PD37-09 INTERMITTENT WST-11 VASCULAR TARGET PHOTODYNAMIC THERAPY IN A MOUSE ORTHOTOPIC BLADDER MODEL

Abstract

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology I (PD37)1 Sep 2021PD37-09 INTERMITTENT WST-11 VASCULAR TARGET PHOTODYNAMIC THERAPY IN A MOUSE ORTHOTOPIC BLADDER MODEL Jie Chen, Jasmine Thomas, Karan Nagar, Lucas Nogueira, Peter Reisz, Kwanghee Kim, and Jonathan Coleman Jie ChenJie Chen More articles by this author , Jasmine ThomasJasmine Thomas More articles by this author , Karan NagarKaran Nagar More articles by this author , Lucas NogueiraLucas Nogueira More articles by this author , Peter ReiszPeter Reisz More articles by this author , Kwanghee KimKwanghee Kim More articles by this author , and Jonathan ColemanJonathan Coleman More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002047.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Vascular targeted photodynamic therapy (VTP) is a non-surgical tumor ablation approach used to treat early-stage prostate cancer and may also be effective for urothelial cancer based on preclinical data in heterotopic models. While orthotopic models are valuable as they reproduce factors such as local tissue environment and cancer progression pathogenesis compared to ectopic implantation, its implementation is technically difficult. Herein we describe our work in developing an orthotopic murine model for bladder urothelial cancer using intermittent laser pulses to ensure mouse survival and local tumor control. METHODS: The MB-49 murine urothelial cancer line was used for all experiments after establishing stable luciferase expression. Tumors were implanted in 16 1C57BL-6 mice by surgical approach by direct injection of 1x105 MB49-Luc cells into the bladder. Successful tumor implantation was assessed by IVIS images 72 hours after implantation. Mice were divided in two groups: control and VTP treated. VTP was performed 96 hours after cell injection at a power of 100mW in 30 seconds pulses, with 30 seconds interval. Mouse bladders were harvested 13 days post implantation. Safety, tumor control, and histology parameters were assessed. RESULTS: Adequate tumor growth was observed in all mice, and no major toxicity was observed in both groups. Final tumor size was 71% smaller, and histological viability was decreased in VTP treated tumors when compared to controls (p <0.001, figure 1). CD31, Ki67 expression were decreased 2.75 and 1.87-fold respectively, and tunnel staining was increased 3.2-fold in control tumors when compared to VTP treated. (p <0.05, figure 2). CONCLUSIONS: A mouse orthotopic bladder urothelial model via injection of MB-49 cell line is feasible and displays a very high tumor take rates. Intermittent VTP treatment has an effect on mouse bladder tumors as shown by the decrease in tumor size, weight and change in histology. Additional refinement to the model may provide a means to establish an appropriate timeline and utility for future studies. Source of Funding: NIH/NCI (P30 CA008748) and the Thompson Family Foundation © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e658-e659 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jie Chen More articles by this author Jasmine Thomas More articles by this author Karan Nagar More articles by this author Lucas Nogueira More articles by this author Peter Reisz More articles by this author Kwanghee Kim More articles by this author Jonathan Coleman More articles by this author Expand All Advertisement Loading ...